OptiBiotix Health Plc announced revenue guidance for the full year 2020. For the period, The company anticipates continued revenue growth in 2020 as existing deals contribute to full year revenues, extend the application of products into new areas, retail partners launch more products and extend their territories, and continue to execute deals with new partners. To support sales growth, anticipate adding new products across portfolio. For LPLDL® these include more dairy products, and expanding development of cardiovascular health portfolio with a blood pressure (CholBiomeBP), and vascular health product (CholBiomeVH).